Pulmonary Hypertension Related to Congenital Heart Disease: A Call to Action




Provided by Integrity Continuing Education, Inc.


Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.


Pulmonary arterial hypertension related to congenital heart disease (CHD-PAH) is a common type of pulmonary arterial hypertension (PAH). Despite this, little emphasis has been given to this group of patients until recently, when compared with idiopathic PAH. This is largely because of the complexity and the wide range of underlying cardiac anatomy and physiology, with a multitude of adaptive mechanisms not fully understood. Pulmonary arterial hypertension related to congenital heart disease is, therefore, best diagnosed and managed in centers specializing in both CHD and PAH to provide state-of-the-art care. We discuss the optimal management of CHD-PAH patients and how to optimize short-and long-term outcomes, based on current knowledge of the condition and the advent of targeted advanced therapies.

Dr. Richard A. Krasuski and Dr. Ioana R. Preston will highlight unmet needs, new pathophysiology insights, and current and emerging therapies in CHD-PAH. In this activity you will be able to test your knowledge with interactive questions and follow a patient case from screening to treatment.


Richard A. Krasuski, MD​
Director of the Adult Congenital Heart Disease Center​
Cardiovascular Medicine​
Duke University Medical Center​
Durham, North Carolina​


Ioana R. Preston, MD​
Associate Director of Medicine, Director of PH Center​
Pulmonary, Critical Care and Sleep Division​
Tufts Medical Center​
Boston, Massachusetts​


Release date: November 23, 2021
Expiration date: November 23, 2022
Estimated time to complete activity: 60 minutes



This program is intended for cardiology and pulmonary specialty HCPs that manage patients with CHD and PAH.

  • List the clinical subtypes of CHD ​
  • Describe the pathophysiology of PAH development in patients with CHD-PAH ​
  • Apply risk factors and determinants of prognosis to the evaluation of patients with CHD and suspected/known PAH​
  • Implement guideline recommendations and efficacy and safety data of PAH pharmacotherapies for treatment of patients with CHD-PAH ​
  • Utilize shared decision-making and multidisciplinary approaches to mitigate adverse events and improve patient satisfaction and quality of life

There are no fees for participating and receiving CME credit for this activity. During the period of November 23, 2021 – November 23, 2022 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Physician Continuing Education Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Richard A. Krasuski, MD​
Consulting Fees: Actelion Pharmaceuticals​
Contracted Research: Actelion Pharmaceuticals​, Adult Congenital Heart Association ​
Investigator: Corvia, CryoLife, Edwards Lifesciences

Ioana R. Preston, MD​
Adjudication Committee: Pfizer

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest